Latham & Watkins Advises IDEAYA Biosciences in Pricing of Public Offering

IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA is selling 7,439,201 shares of common stock and pre-funded warrants to purchase 2,020,270 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of US$18.50 per share, before underwriting discounts and commissions, and the pre-funded warrants are being sold at a public offering price of US$18.4999 per pre-funded warrant. The exercise price of the pre-funded warrants is US$0.0001 per share. In addition, IDEAYA has granted the underwriters a 30-day option to purchase up to an additional 1,418,920 shares of its common stock at the public offering price per share, before underwriting discounts and commissions. The aggregate gross proceeds to IDEAYA from this offering are expected to be approximately US$175,000,000, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants.

Latham & Watkins LLP represents IDEAYA Biosciences, Inc. in the offering with a corporate team led by Bay Area partner Mark Roeder, with Orange County associates Eric Hanzich, Tiana Baghdikian, Caitlin Nguyen, and Amy Lutfi. Advice was provided on IP matters by Bay Area partner Christopher Hazuka, on employee benefits and compensation matters by Bay Area partner James Metz; on tax matters by Bay Area partner Grace Lee, with associate Alexandra O’Keefe; on FDA regulatory matters by Washington, D.C. partner John Manthei, Bay Area partner Betty Pang and San Diego counsel Amy Speros.